Major drugs to be hit by Colombian price cuts
This article was originally published in Scrip
A range of major products from leading multinationals are to have their prices reduced in Colombia by an average of 40%, in an effort to bring their price levels more into line with those in international markets.
You may also be interested in...
The bedding-in period is ending for Europe’s one-year-old system for preventing the circulation of fake medicines, and the scheme is gearing up for a more fully operational stage.
EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.